India's Hidden Gems
Discover promising small and mid-cap Indian companies with explosive growth potential. These carefully selected stocks benefit from government spending, economic momentum, and renewed foreign investment before they become mainstream success stories.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
India MSCI ETF iShares
INDA
Current price
$53.65
Provides broad, diversified exposure to the overall Indian equity market, benefiting from the macroeconomic tailwinds like government capex that are d...
Provides broad, diversified exposure to the overall Indian equity market, benefiting from the macroeconomic tailwinds like government capex that are driving the rally.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
India's economy is experiencing powerful tailwinds from government infrastructure spending and foreign investment. These macroeconomic forces are creating perfect conditions for small and mid-cap companies to achieve remarkable growth, with some recent stocks delivering returns exceeding 500%.
What You Need to Know
This collection includes both focused ETFs and individual companies across infrastructure, manufacturing, IT, and financial services. These stocks represent opportunities beyond traditional large-cap blue chips, capturing the next wave of Indian market growth.
Why These Stocks
Each company or fund was selected for its potential to benefit directly from India's expanding economy and increased government spending. These options let you invest in promising Indian market segments before these companies become household names.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+25.20%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 25.2% over the next year.
Stocks Rated Buy by Analysts
7 of 13 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Hidden Multibaggers
Some lesser-known Indian stocks have already delivered returns exceeding 500%. This collection helps you discover the next potential multibagger before everyone else does.
Riding Government Spending Wave
India's massive infrastructure push creates a golden opportunity for companies in this group. They're perfectly positioned to benefit from billions in government spending across key sectors.
Beyond The Big Names
While everyone focuses on India's famous blue-chips, these smaller companies offer potentially higher growth trajectories. These are the companies that could become tomorrow's market leaders.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.